Drug Profile

CK 271

Alternative Names: CK-271; CK-3772271

Latest Information Update: 28 Oct 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cytokinetics
Class Cardiovascular therapies; Small molecules
Mechanism of Action Cardiac myosin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Hypertrophic cardiomyopathy

Most Recent Events

28 Oct 2023 No recent reports of development identified for phase-I development in Hypertrophic-cardiomyopathy(In volunteers) in Unknown
25 Feb 2021 Cytokinetics completes a phase I trial in Hypertrophic cardiomyopathy (In volunteers) in Unknown (unspecified route)
16 Nov 2020 Pharmacodynamics data from preclinical trial in Hypertrophic cardiomyopathy released by Cytokinetics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com